Parry-Romberg syndrome is a rare, acquired disorder characterized by progressive unilateral facial atrophy of the skin, soft tissue, muscles, and underlying bony structures that may be preceded by cutaneous induration. It is sometimes accompanied by ipsilateral brain lesions and neurological symptoms. Here we present the case of a 10-year-old girl with right-sided PRS and recurrent monoplegic ataxia of the left leg. At 4 years of age, she presented with localized scleroderma over the right parietal region of her scalp; her face gradually became asymmetric as her right cheek atrophied. Brain magnetic resonance imaging revealed hemiatrophy of the face and skull base, and T2-weighted images showed increased signal in the right hemipons and hemicerebellar peduncle. Magnetic resonance angiography findings were unremarkable. She was treated with oral prednisolone, and her recurrent gait ataxia diminished within 2 months of the follow-up period. To the best of our knowledge, this is only the second case of PRS presenting with an abnormal involvement of the ipsilateral hemipons.

Key words: Parry-Romberg syndrome, Child, Magnetic resonance imaging, Brain stem, Ataxia

Introduction

Parry-Romberg syndrome (PRS), or progressive facial hemiatrophy, is a rare disorder presenting as a slowly progressive but self-limited atrophy of facial structures, sometimes followed by wasting of adjacent skin, connective or ocular tissue, muscle, cartilage, and bone. Symptoms usually appear in the first or second decades of life, but a few cases with a late onset have been described. It slowly progresses over 2 to 20 years before stabilizing. PRS is more common in females, and is believed to be sporadic, although some rare familial cases have been reported.

Although some PRS patients are neurologically normal, diverse neurologic symptoms have been reported, most commonly seizures and headache. Neuroimaging can disclose intracranial abnormalities, even in asymptomatic patients. Common magnetic resonance imaging (MRI) findings include ipsilateral high signal intensity in the white matter or gray matter, leptomeningeal enhancement, cerebral atrophy, and intracranial vascular malformation. Neurologic symptoms were not always associated with intracranial abnormalities.

We present a unique case, a 10-year-old girl in whom PRS presented on the right face, who later had recurrent episodes of monoplegic ataxia. Brain MRI revealed very few findings with an increased signal at the ipsilateral hemipons and hemicerebellar peduncle.
Case report

The patient, a 10-year-old Korean girl, is the younger daughter of two children. She was born healthy and her family history was unremarkable. At the age of 4 years, her parents discovered mild hair loss over the right parietal region of her scalp, over an area of about 1 cm in diameter that slowly increased in size, centered around a small white papule (Fig. 1A, B). Diagnosis of localized scleroderma was made based on clinical features, and topical steroids were administered. The lesions slowly evolved over one year and became perpendicularly elongated with consequent atrophy, but without hyperpigmentation, and remained static after a year. Beginning from the age of 6 years, her face gradually became asymmetric atrophy on her right cheek, and worsened over the following two years. Unfortunately, the comprehensive evaluation was not performed by local orthopedic care despite her asymmetric facial atrophy. At the age of 10 years, she visited for sudden-onset ataxic gait on the left side two months prior. She had recurrent episodes of numbness, paresthesia, and limpness in her left leg, followed by falling down to the left side. Her arms were unaffected. These symptoms lasted one to two hours and spontaneously recovered. There was no history of headaches, visual dysfunction, or seizures and no history of recent viral infection or trauma. There was no family history of scleroderma, neurologic, rheumatologic, or autoimmune disease.

Physical examination revealed subcutaneous atrophy of the whole right hemiface, and a 3×0.5-cm linear scleroderma “en coup de sabre” (LSCS) in the right paramedian frontal area without skin discoloration (Fig. 1C, D). She was mentally alert and had normal intelligence. Meningismus was absent. Function of all cranial nerves was normal. Motor examination revealed 2 to 3 degrees of left leg weakness, but deep tendon reflexes were present in both legs without ankle clonus or Babinski responses. She showed deficits of the cerebellar function tests such as Romberg test, tandem gait, finger-to-nose test, and rapid alternating movements. General examination revealed no atrophy of the trunk on the same side or the ipsilateral limb.

Hematological and biochemical laboratory findings revealed normal values. Erythrocyte sedimentation rate and C-reactive protein were normal. Results of a hypercoagulable screen were negative. An autoantibody profile showed the presence of antinuclear antibodies at low titers (1:40, homogeneous). Rheumatoid factor was present at 19.2 IU/mL (range, 0–20 IU/mL). Antidouble stranded DNA, anti–ScI-70, lupus anticoagulant, anticardiolipin antibody, anticentromere, and test for syphilis (venereal disease research laboratory) were all negative. The cerebrospinal fluid was acellular, with normal protein and glucose. Oligoclonal bands were not detected. X-rays of the skull and face revealed no evidence of fracture, and abdominal sonography did not yield abnormalities.

MRI of the brain showed a hemiatrophy of right side facial structure and skull base underlying skin lesion. An increased signal was found at ipsilateral hemipons and hemicerebellar peduncle (Fig. 2). Magnetic resonance angiograms of the brain were unremarkable. An electroencephalogram did not show pathological findings. The diagnosis that best accounts for our patient’s symptoms, disease course, and laboratory and MRI findings is PRS with recurrent monoplegic ataxia due to ipsilateral hemipons involvement.

She was treated with oral prednisolone of 30 mg daily (1.2 mg/kg/day administered 3 times) for 2 months including a tapering period. Recurrent episodes of her ataxic gaits diminished within two months of follow-up period. Additionally, there was no progression of facial hemiatrophy or other neurological deficits for more than 3 years of observing the patient.

Discussion

First described by Parry (1825), the prevalence is unknown, but Stone\(^4\) suggested 1/500,000 births are positive for PRS. The disease usually begins during the first or second decades of life\(^3,9\).
The progression of atrophy usually lasts from two to 10 years and then the process seems to enter a stable phase. The final condition of facial deformity may depend on the duration of the disease.

PRS has been linked with many systemic manifestations including dermatologic, neurologic, ophthalmologic, cardiac, rheumatologic, infectious, endocrine, and maxillofacial fields. Seizures are the most common neurologic manifestation. Seizures were documented as being medically intractable in 33% of patients. Other symptoms associated with PRS were as follows: headaches, movement disorders secondary to brain lesions, trigeminal neuralgia, hemiplegic migraines, behavioral changes, sympathetic hyperactivity, progressive intellectual deterioration due to cerebral hemiatrophy (Rasmussen encephalitis), oculomotor nerve palsy, facial nerve palsy and even death due to brainstem involvement.

The most common findings on MRI are usually ipsilateral T2 hyperintensity, mostly in white-matter, gray matter and corpus callosum. Other findings are as follows: leptomeningeal enhancement, calcification, cerebral atrophy, intracranial vascular malformation, focal corpus callosum infarctions, ipsilateral infarcts in amygdaloid body, and ipsilateral meningeal and basal ganglia lesions. Neuroimaging findings in patients with PRS were frequently ipsilateral, although, contralateral findings have been reported. To the best of our knowledge, only two cases of PRS with the T2 hyperintensity in the ipsilateral hemipons, including our patient, have been reported. A two-year-old boy with PRS had many severe neurologic dysfunctions including seizures, dysarthria, oculomotor nerve palsy, and dysphagia. MRI revealed progressive atrophy of right cerebral hemisphere, and right midbrain and pons lesions. At the age of five years, he died in his sleep despite treatment with intravenous immunoglobulin and cyclophosphamide. Our patient with PRS presented with recurrent episodes of monoplegic ataxia, and increased signal at ipsilateral hemipons and hemicerebellar peduncle on brain MRI. We presumed that the abnormal involvement of ipsilateral pons was associated with her symptoms. A follow-up MRI was planned after the treatment of steroid, but was not performed, because her parents were very concerned about recurrent use of sedative drug. We could not absolutely demonstrate, just might speculate, the correlation between a decline of ataxic gait and any improvement of neuroimaging.

The pathogenesis of PRS is not well understood and numerous etiologies have been suggested, including trauma, infection, autoimmune processes, and cervical sympathetic dysfunction.
Autoimmune reaction appears to be the favored hypothesis in some patients, based upon coexisting autoantibodies such as antinuclear antibodies, antidualle strand DNA, anticytoplasm antibodies, rheumatoid factors, and oligoclonal bands in the cerebrospinal fluid, and good response to immunosuppressive therapy. Inflammatory process, particularly vasculitis, is suspected in neurologic involvement of PRS. Brain biopsies have been performed in some children, revealing perivascular lymphocytic infiltrate, and gliosis and sclerosis of the leptomeninges suggesting an inflammatory process. Hyperactivity of the brain stem center has also been suggested as a cause of PRS. In our patient, MRI discovered T2 hyperintensities at the ipsilateral hemipons, and her recurrent episodes of ataxic gaits gradually improved after the oral steroid trial, although all laboratory findings for autoimmune profiles and hypercoagulable screens were negative. Therefore, we speculated that abnormal autoimmune reaction and hyperactivity of the brain stem might be involved in her disease.

Chiu et al. reported a high rate of neurologic symptoms (28% to 65%) and neuroimaging abnormalities (19% to 73%) in children with PRS by institutional and literature review. However, neurologic symptoms were not correlated with neuroimaging abnormalities, and there was poor correlation between the severity of the cutaneous lesions and MRI findings. They recommended that all children with PRS or LSCS have a brain MRI performed at initial diagnosis, and that systemic immunosuppressive medication should be strongly considered for children found to have intracranial abnormalities. Early detection of neurologic involvement is important because it affects treatment options. Our patient was treated with oral prednisolone and the episodes of ataxic gaits gradually improved within two months without relapse or progression or other neurological deficits for more than three years of observing the patient.

We present a very curious patient with PRS who had recurrent monoplegic ataxia due to ipsilateral hemipons involvement without fatal neurological deterioration. Because clinical predictors of intracranial abnormalities are poor, neuroimaging should be strongly considered before starting treatment as a baseline examination to identify intracranial lesions and to determine therapeutic plans, although the children may be asymptomatic.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**References**

1. Stone J, Franks AJ, Guthrie JA, Johnson MH. Scleroderma “en coup de sabre”: pathological evidence of intracerebral inflammation. J Neurol Neurosurg Psychiatry 2001;70:382-5.
2. Duyan CM, Karabekmez FE, Keskin M, Tosun Z. Parry-Romberg syndrome: facial atrophy and its relationship with other regions of the body. Ann Plast Surg 2009;63:457-61.
3. Carreno M, Donaire A, Barcelo MI, Rumia J, Falip M, Agudo R, et al. Parry Romberg syndrome and linear scleroderma in coup de sabre mimicking Rasmussen encephalitis. Neurology 2007;68:1308-10.
4. Stone J. Parry-Romberg syndrome: a global survey of 205 patients using the Internet. Neurology 2003;61:674-6.
5. Kister I, Inglese M, Laxer RM, Herbert J. Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology 2008;71:1538-45.
6. Chiu YE, Vora S, Kwon EK, Maheshwari M. A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. Pediatr Dermatol 2012;29:738-48.
7. Cory RC, Clayman DA, Faillace WJ, McKee SW, Gama CH. Clinical and radiologic findings in progressive facial hemiatrophy (Parry-Romberg syndrome). AJNR Am J Neuroradiol 1997;18:751-7.
8. Moko SB, Mistry Y, Blandin de Chalain TM. Parry-Romberg syndrome: intracranial MRI appearances. J Craniofac Surg 2003;14:321-4.
9. Qureshi UA, Wani NA, Altuf U. Parry-Romberg syndrome associated with unusual intracranial vascular malformations and Phthisis bulbi. J Neurol Sci 2010;291:107-9.
10. El-Kehdy J, Abbas O, Rubeiz N. A review of Parry–Romberg syndrome. J Am Acad Dermatol 2012;67:769-84.
11. Gambichler T, Kreuter A, Hoffmann K, Bechara FG, Altmeyer P, Jansen T. Bilateral linear scleroderma "en coup de sabre" associated with facial atrophy and neurological complications. BMC Dermatol 2001;1:9.
12. Drummond PD, Hassard S, Finch PM. Trigeminal neuralgia, migraine and sympathetic hyperesthesia in a patient with Parry-Romberg syndrome. Cephalalgia 2006;26:1146-9.
13. Sathornsumetee S, Schanberg L, Weisleder P. Parry-Romberg syndrome with fatal brainstem involvement. J Pediatr 2005;146:429-31.
14. Lonchamp P, Emilie J, Pelier-Cady MC, Cadou B, Barthelaix A. Central sympathetic dysregulation and immunological abnormalities in a case of progressive facial hemiatrophy (Parry-Romberg disease). Clin Auton Res 1995;5:199-204.
15. Gonul M, Dogan B, Izc Y, Varol G. Parry-Romberg syndrome in association with anti-dsDNA antibodies: a case report. J Eur Acad Dermatol Venereol 2005;19:740-2.